KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Long-Term Investments: 2014-2024

Historic Long-Term Investments for Arbutus Biopharma (ABUS) over the last 7 years, with Sep 2024 value amounting to $3.0 million.

  • Arbutus Biopharma's Long-Term Investments fell 71.76% to $3.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $3.0 million, marking a year-over-year decrease of 71.76%. This contributed to the annual value of $6.3 million for FY2023, which is 83.18% down from last year.
  • Arbutus Biopharma's Long-Term Investments amounted to $3.0 million in Q3 2024, which was down 54.59% from $6.5 million recorded in Q2 2024.
  • In the past 5 years, Arbutus Biopharma's Long-Term Investments registered a high of $56.3 million during Q1 2022, and its lowest value of $1.6 million during Q2 2020.
  • Its 3-year average for Long-Term Investments is $25.2 million, with a median of $11.1 million in 2023.
  • Per our database at Business Quant, Arbutus Biopharma's Long-Term Investments crashed by 88.87% in 2020 and then spiked by 81.55% in 2022.
  • Quarterly analysis of 5 years shows Arbutus Biopharma's Long-Term Investments stood at $1.6 million in 2020, then reached $35.7 million in 2021, then increased by 4.69% to $37.4 million in 2022, then crashed by 83.18% to $6.3 million in 2023, then plummeted by 71.76% to $3.0 million in 2024.
  • Its last three reported values are $3.0 million in Q3 2024, $6.5 million for Q2 2024, and $8.7 million during Q1 2024.